HIV I Infection Clinical Trial
Official title:
Effect of an Mobile Health Intervention on Adherence to Antiretroviral Treatment in Adult Patients Living With HIV Compared to Standard Care
NCT number | NCT05187741 |
Other study ID # | 138/21 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2022 |
Est. completion date | November 15, 2022 |
Verified date | November 2022 |
Source | Hospital Civil de Guadalajara |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized clinical trial across the whole of the patients who attend the HIV Unit of the Hospital Civil Viejo, a sample calculated in 43 patients for each group (intervention and control). Patients who have HIV infection and are starting antiretroviral treatment (ART), who are between 18 and 50 years old and have a mobile device, will be included in the study. The messages will consist of medical appointment reminders and adherence and motivational messages for a period of six months.
Status | Completed |
Enrollment | 80 |
Est. completion date | November 15, 2022 |
Est. primary completion date | November 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Recently diagnosed with HIV infection . starting with antiretroviral therapy and haven't taken ART before - Patients with the status of "lost to follow up" who return to re-initiate ART Exclusion Criteria: - Patients who are participating in other study - patients above 18 years old - Patients who does not have signal phone at their residency - Those who refuses to participate in the study |
Country | Name | City | State |
---|---|---|---|
Mexico | Hospital Civil de Guadalajara "Fray Antonio Alcalde" | Guadalajara | Jalisco |
Lead Sponsor | Collaborator |
---|---|
Hospital Civil de Guadalajara |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | antiretroviral treatment adherence | The practice of patients where they take their medications as prescribed. To proceed with the calculation, the following formula should be applied: [(number of units dispensed - number of units remaining) / (prescribed number of units per day x number of days between the two visits)] x 100. | 6 months | |
Secondary | care retention | Person living with HIV who enters and remains in comprehensive HIV care by health services, according to their needs. It is recorded at 6 months and 12 months of follow-up, with the patient's compliance with their medical appointments. | 6 months | |
Secondary | HIV viral loal | Amount of genetic material (RNA) of the virus in blood in the most recent determination.Measure by Reverse transcriptase polymerase chain reaction test reported as copies/ml | 6 months | |
Secondary | TCD4+ count in blood | Number of CD4 + T lymphocytes in the blood. Measure by flow cytometry and reported as cells/mm3 | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04585737 -
Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF
|
Phase 4 | |
Not yet recruiting |
NCT06282783 -
Studying Topiramate for Re-Activating the HIV-1 Reservoir
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03622177 -
Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection
|
||
Recruiting |
NCT05854381 -
To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV
|
Phase 1 | |
Enrolling by invitation |
NCT05071378 -
Leveraging Family-Based Assets for Black MSM In House Ball Communities
|
N/A | |
Completed |
NCT05421806 -
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
|
||
Completed |
NCT04568395 -
Acute Effects of TCIG vs ECIG in PLWH
|
N/A | |
Recruiting |
NCT04887675 -
Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI
|
N/A | |
Recruiting |
NCT04820933 -
Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
|
Early Phase 1 | |
Completed |
NCT03584048 -
Charlotte Retention in Care Study
|
||
Recruiting |
NCT06005610 -
Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy
|
Phase 2 | |
Recruiting |
NCT05947890 -
Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa
|
Phase 2 | |
Recruiting |
NCT05187429 -
Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05601128 -
A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
|
Phase 3 | |
Completed |
NCT04675255 -
Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism
|
N/A | |
Recruiting |
NCT05110963 -
Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments
|
N/A | |
Completed |
NCT03986099 -
Community Based Antiretroviral Therapy (CBART) Among Children on Chronic ART
|
N/A | |
Completed |
NCT04971343 -
Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
|
||
Completed |
NCT04725877 -
VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04618198 -
Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa
|
Phase 3 |